Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of β-L-FD4C as potent anti-HBV agent

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 1, 1998, Pages 57-62

  Li, Xiuyan ^a   Carmichael, Ellen ^a   Feng, Ming ^a   King, Ivan ^a   Doyle, Terrence W ^a   Chen, Shu Hui ^a  

^a Vion Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ELVUCITABINE; NUCLEOSIDE ANALOG; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL SURVIVAL; HEPATITIS B VIRUS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PRODRUGS; TUMOR CELLS, CULTURED; ZALCITABINE;

ANIMALIA; HEPATITIS B VIRUS;

EID: 0032488586     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10178-0     Document Type: Article

References (23)

1. 1. De Clercq, E. Adv. Drug Res. 1988, 17, 1.
2. 2. (a) Mansuri, M. M.; Starett, J. E.; Ghazzouli, L; Hitchcock, M. J. M.; Sterzycki, R. Z.; Brankovan, V.; Lin, T-S.; August, E. M.; Prusoff, W. H.; Sommadossi, J-P.; Martin, J. C. J. Med. Chem. 1989, 32, 461.
3. (b) recent review: Nair, V.; Jahnke, T. S. Antimicrob. Agents Chemother. 1995, 39, 1017.
4. 3. c.f. Johnson, M. A.; Ahluwalia, G.; Connelly, M. C; Cooney, D. A.; Broder, S.; Johns, D. G.; Fridland, A. J. Biol. Chem. 1988, 263, 15354.
5. 4. c.f. Chang, C-N.; Doong, S-L.; Zhou, J. H.; Beach, J. W.; Jeong, L. S.; Chu, C. K.; Tasi, C-H.; Cheng, Y-C. J. Biol. Chem. 1992, 267, 13938.
6. 5. Lin, T-S.; Luo, M-Z.; Liu, M-C.; Zhu, Y-L.; Gullen, E.; Dutschman, G. E.; Cheng, Y-C. J. Med. Chem. 1996, 39, 1757.
7. 6. Gosselin, G.; Girardet, J-L.; Perigaud, C.; Benzaria S.; Lefebvre, L; Schlienger, N.; Pompon, A.; Imbach, J-L. Acta Biochimica Polonica 1996, 43, 195.
8. 7. For example, ddU was devoid of antiviral activity in the absence of thymidine kinase.
9. 8. Lefebvre, I.; Perigaud, C.; Pompon, A.; Aubertin, A-M.; Girardet, J-L.; Kirn, A.; Gosselin, G.; Imbach, J-L. J. Med. Chem. 1995, 38, 3941.
10. 9. Girardet, J-L.; Perigaud, C.; Aubertin, A-M.; Gosselin, G.; Kirn, A.; Imbach, J-L. Bioorg. Med. Chem. Lett. 1995, 5, 2981.
11. 10. Perigaud, C.; Aubertin, A-M.; Benzaria, S.; Pelicano, H.; Girardet, J-L.; Kirn, A.; Gosselin, G.; Imbach, J-L. Biochem. Pharmacol 1994, 48, 11.
12. 11. Chu, C. K.; Babu, J. R.; Beach, J. W.; Ahn, S. K.; Huang, H.; Jeong, L. S.; Lee, S. J. J. Org. Chem. 1990, 55, 1418.
13. 12. Taniguchi, M.; Koga, K.; Yamada, S. Tetrahedron 1974, 30, 3547.
14. 13. Chen, S. H.; Li, X.; Li, J.; Niu, C.; Carmichael, E.; Doyle, T. W. J. Org. Chem. 1997, 62, 3449.
15. 14. c.f. Valette, G.; Pompon, A.; Girardet, J-L.; Cappedana, C.; Franchetti, P.; Grifantini, M.; Colla, P. L.; Loi, A.G.; Perigaud, C; Gosselin, G.; Imbach, J-L. J. Med. Chem. 1996, 39, 1981.
16. 3) δ 7.66 (d, J=6.0 Hz, 1H), 7.06 (bs, 1H), 6.29-6.27 (m, 1H), 6.03-6.00 (m, 1H), 5.04 (bs, 1H), 4.31-4.28 (m, 2H), 4.17-4.09 (m, 4H), 3.19-3.14 (m, 4H), 2.37-2.36 (m, 6H).
17. +): 512.0727; found: 512.0727.
18. D of (8) = +8.55° (c 0.70, MeOH).
19. 16. (a) Sells, M. A.; Chen, M.-L. Acs,G.Proc. Natl Acad. Sci. U.S.A. 1987, 84, 1005.
20. (b) Sells, M. A.; Zelent, A. Z.; Shvartsman, M.; Acs, G. J. Virol. 1988, 62, 2836.
21. 17. Korba, B.E. and G. Milman.Antiviral Research 1991, 15, 217.
22. 18. Mosmann, T. J. Immunol. Meth. 1983, 65, 55.
23. 19. The first example of using SATE group, see: Perigaud, C.; Gosselin, G.; Lefebvre, I.; Girardet, J-L.; Benzaria, S.; Barber, I.; Imbach, J-L. Bioorg. Med. Chem. Lett. 1993, 3, 2521.